ӰԺ

header-logo
protein structures and brain images
Balaraman Kalyanaraman

Balaraman Kalyanaraman, PhD

Harry R. & Angeline E. Quadracci Professor in Parkinson’s Research

Locations

  • Biophysics
    MFRC 2034

Contact Information

Education

Research Associate (Postdoctoral), National Biomedical ESR Center, ӰԺ, Milwaukee, WI, 1981-1984
Visiting Fellow, Chemistry, Laboratory of Environmental Biophysics, National Institute of Environmental Sciences, Research Triangle Park, NC, 1978-1981
PhD, Chemistry, University of Alabama, Tuscaloosa, AL, 1978
MS, Chemistry, Indian Institute of Technology, Mumbai (formerly Bombay), India, 1972
BS, Chemistry, Loyola College, University of Madras, Chennai, India, 1970

Biography

I received my BS in chemistry from Loyola College, University of Madras in India, my MS in chemistry from the Indian Institute of Technology in India, and my PhD in chemistry from University of Alabama. I completed my postdoctoral training in chemistry at the Laboratory of Environmental Biophysics at the National Institute of Environmental Sciences. I came to ӰԺ as a research associate at the National Biomedical EPR Center in 1984, and was appointed as ӰԺ faculty in 1994. I served as director of the Biophysics Research Institute from 2000 to 2003, and as chair of the Department of Biophysics from 2003 to 2022. Also, I have served as an associate editor for Free Radicals in Biology and Medicine, Free Radical Research, and Biochemical Journal.

Research Interests

My research centers on understanding the role of oxidants, antioxidants, and mitochondrial therapeutics in cancer biology, immuno-oncology, cardio-oncology, and neurodegeneration.

My specific research areas are outlined below.

  • Chemistry and Biophysics
    • Detection of reactive oxygen and nitrogen species by EPR spin-trapping, fluorescence, optical stopped-flow, and HPLC techniques
    • Syntheses of mitochondrially targeted spin traps, spin labels, and ROS-specific fluorescence probes
    • EPR studies of mitochondria
  • Mechanism of Signal Transduction/Cell Signaling
    • Mitochondrial STAT3 and redox signaling
    • Oxidant-induced iron signaling and apoptosis
    • Chemotherapeutic drug (e.g., doxorubicin) toxicity and prevention; mechanism of apoptosis in tumor cells and normal cells
  • Mechanism of Disease
    • Role of mitochondria-derived oxidants in chemically induced Parkinsonism (e.g., MPTP, rotenone) in cell culture and animal models; mechanism of protein aggregation, proteosomal dysfunction, and apoptotic neuronal cell death
    • Targeting of metabolism, bioenergetics, and redox signaling in cancer
    • Development of new mitochondria-targeted antitumor and antiproliferative drugs

My research projects include the following:

  • Chemoprevention of Lung Cancer by Targeting Lonidamine to Mitochondria
    The goal is to examine the efficacy and mechanism of a novel mitochondrial targeting agent (Mito-LON) in treating lung cancer and brain metastasis.

  • Chemoprevention of Lung Cancer with Mitochondria-targeted Honokiol
    The goal is to evaluate the chemopreventive potential of Mito-HNK, a mitochondria-targeted compound, using both in vitro and in vivo models of lung adenocarcinoma (LUAD) and determine its mechanism of action, to determine its efficacy for inhibiting LUAD progression and metastasis and its suitability for human clinical trials.
     

Lab Members
Gang Cheng, Assistant Professor

Publications

  • (Kalyanaraman B, Cheng G, Hardy M.) Arch Biochem Biophys. 2024 Nov;761:110172 PMID: 39369836 SCOPUS ID: 2-s2.0-85205522642 10/07/2024

  • (Cheng G, Hardy M, Hillard CJ, Feix JB, Kalyanaraman B.) Commun Biol. 2024 May 30;7(1):668 PMID: 38816577 PMCID: PMC11139878 SCOPUS ID: 2-s2.0-85194991828 05/31/2024

  • (Beerkens APM, Boreel DF, Nathan JA, Neuzil J, Cheng G, Kalyanaraman B, Hardy M, Adema GJ, Heskamp S, Span PN, Bussink J.) Cancer Metab. 2024 May 03;12(1):13 PMID: 38702787 PMCID: PMC11067257 05/04/2024

  • (Kalyanaraman B, Cheng G, Hardy M.) Redox Biol. 2024 May;71:103092 PMID: 38377788 PMCID: PMC10891329 SCOPUS ID: 2-s2.0-85185575430 02/21/2024

  • (Xiong D, Yin Z, Huang M, Wang Y, Hardy M, Kalyanaraman B, Wong ST, You M.) Cancer Commun (Lond). 2024 Mar;44(3):448-452 PMID: 37930151 PMCID: PMC10958673 SCOPUS ID: 2-s2.0-85176136734 11/06/2023

  • (Ay M, Charli A, Langley M, Jang A, Padhi P, Jin H, Anantharam V, Kalyanaraman B, Kanthasamy A, Kanthasamy AG.) Front Neurosci. 2024;18:1356703 PMID: 38449738 PMCID: PMC10915001 03/07/2024

  • (Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Free Radic Biol Med. 2023 Aug 20;205:175-187 PMID: 37321281 PMCID: PMC11129726 SCOPUS ID: 2-s2.0-85162228734 06/16/2023

  • (Cheng G, Hardy M, Kalyanaraman B.) Sci Rep. 2023 May 04;13(1):7254 PMID: 37142668 PMCID: PMC10160116 SCOPUS ID: 2-s2.0-85158068757 05/05/2023

  • (Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Cancers (Basel). 2023 Feb 08;15(4) PMID: 36831432 PMCID: PMC9953882 02/26/2023

  • (Kalyanaraman B, Cheng G, Hardy M, You M.) Expert Opin Ther Targets. 2023;27(10):939-952 PMID: 37736880 PMCID: PMC11034819 SCOPUS ID: 2-s2.0-85173986031 09/22/2023

  • (Kalyanaraman B.) Redox Biol. 2022 Nov;57:102497 PMID: 36242913 PMCID: PMC9563555 SCOPUS ID: 2-s2.0-85139734287 10/16/2022

  • (Michalski R, Smulik-Izydorczyk R, Pięta J, Rola M, Artelska A, Pierzchała K, Zielonka J, Kalyanaraman B, Sikora AB.) Front Chem. 2022;10:930657 PMID: 35864868 PMCID: PMC9294461 07/23/2022